Armando Anido

Type: Person
Name: Armando Anido
First reported Oct 15 2014 - Updated Oct 15 2014 - 2 reports

Zynerba Pharmaceuticals Raises $13 Million to Develop First and Only Transdermal Cannabinoid Therapies

RADNOR, Pa."We thank our new investors for their confidence in Zynerba as the first and only transdermal cannabinoid company," said Armando AnidoAbout Zynerba Pharmaceuticals Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal ... [Published Stock Nod - Oct 15 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Jason Rhodes joins Atlas Venture investing team

Atlas VentureJason Rhodes joined the investing team.Biotech> NewLink Genetics ( $NLNK ) has appointed Jack Henneman as executive vice president and chief financial officer. Release> Bio-Rad Laboratories ($BIO) has appointed John Goetz as chief operating ... [Published FierceBiotech - Oct 03 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 3 reports

Zynerba Pharmaceuticals Builds Management Team

Medical, Development and Legal Leadership NamedRADNOR, Pa., Oct. 1, 2014 /PRNewswire/ -- Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, today named three ... [Published Scottrade - Oct 01 2014]

Quotes

"we thank our new investors for their confidence in zynerba as the first and only transdermal cannabinoid company" said Armando Anido
...confidence in Zynerba as the first and only transdermal cannabinoid company," said Armando Anido , chairman and CEO of Zynerba Pharmaceuticals. "this funding allows us to advance our two highly innovative and proprietary cannabinoid therapeutic development assets for large unmet patient populations. we believe these novel, synthetically produced candidates may offer unique advantages by delivering drug through the skin and into the bloodstream, presenting significant promise to patients."
...in building a first-rate executive team with these vital executive positions," said Armando Anido, chairman and CEO of Zynerba Pharmaceuticals. "dr. gutterman, ms. o'neil and ms. hanlon offer experience in transdermal development, regulatory approval and launch preparation, allowing zynerba to capitalize on their knowledge and expertise as we work to advance our pipeline for the millions of patients who suffer from chronic and debilitating diseases such as fibromyalgia, neuropathic pain, chronic cancer pain, epilepsy and rheumatoid arthritis."
...neuropathic pain, chronic cancer pain, epilepsy and rheumatoid arthritis," said Armando Anido, chairman and CEO of Zynerba Pharmaceuticals. "these novel synthetically produced candidates may offer unique advantages by delivering drug through the skin and into the bloodstream. terri and i believe that these proprietary treatments, combined with a large population of underserved patients, offer significant promise, and we look forward to advancing our pipeline."

More Content

All (7) | News (6) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Zynerba Pharmaceuticals Raises $13 Million to D... [Published Stock Nod - Oct 15 2014]
Zynerba Pharmaceuticals Raises $13 Million to D... [Published Indianapolis Business Journal - Oct 15 2014]
Jason Rhodes joins Atlas Venture investing team [Published FierceBiotech - Oct 03 2014]
Zynerba Pharmaceuticals Builds Management Team [Published Scottrade - Oct 01 2014]
Zynerba Pharmaceuticals Builds Management Team [Published Pettinga Financial Advisors - Oct 01 2014]
Zynerba Pharmaceuticals Appoints New Leadership... [Published TickerTech.com - Oct 01 2014]
Zynerba Pharmaceuticals Appoints New Leadership... [Published PR Newswire: General Business - Oct 01 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Zynerba Pharmaceuticals Appoints New Leadership... [Published PR Newswire: General Business - Oct 01 2014]
RADNOR, Pa., Oct. 1, 2014 /PRNewswire/ -- Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, today named two leading industry veterans with track records of ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.